Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DBS-002 (thaumatin) is a recombinant sweet-tasting protein being developed by Dandu Biosciences as a non-caloric sweetener and flavor enhancer for the management of metabolic disorders, including diabetes and obesity. Thaumatin is a highly potent sweet-tasting protein originally derived from the West African katemfe fruit (*Thaumatococcus daniellii*). It is known for its intense sweetness, which is several thousand times that of sucrose on a weight basis. By acting as an agonist at the T1R2/T1R3 sweet taste receptor heterodimer, DBS-002 provides a sweet taste without the caloric content or glycemic impact associated with traditional sugars. Dandu Biosciences utilizes a recombinant production platform to manufacture the protein, aiming to provide a scalable and consistent source for use in therapeutic diets and potentially as a direct metabolic intervention. The program is currently in the preclinical proof-of-concept stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thaumatin.